The deal will likely be a function of the market cap at the time. If the market isn't properly valuing FTT then it makes more sense for pharma to acquire. If (heaven forbid) FTT was more fully valued then a co-development deal with product sales rights attaches becomes more likely.
book, page-155
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
